Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Surmodics, Inc. designs and manufactures medical devices. The Company offers coronary stent systems, angioplasty catheters, chronic total occlusion devices, specialty guide wires, and intravascular sensors. Surmodics markets its products in the United States.
Website: sempra.com



Growth: Bad revenue growth rate -12.5%, there is slowdown compared to average historical growth rates 11.9%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +9.8%

Profitability: LTM EBITDA margin is negative, -3.3%. On average the margin is decreasing steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.12 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 69.2% higher than minimum and 31.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.6x by EV / Sales multiple , the company can be 53.7% overvalued

Key Financials (Download financials)

Ticker: SRDX
Share price, USD:  (0.0%)28.99
year average price 36.19  


year start price 42.00 2024-06-13

max close price 42.24 2024-07-09

min close price 26.71 2025-03-12

current price 28.99 2025-06-12
Common stocks: 14 278 000

Dividend Yield:  0.0%
EV / Sales: 3.4x
Margin (EBITDA LTM / Revenue): -3.3%
Fundamental value created in LTM:
Market Cap ($m): 414
Net Debt ($m): -1
EV (Enterprise Value): 413
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-01zacks.com

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

2025-04-04zacks.com

SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System

2025-03-06businesswire.com

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

2025-02-03zacks.com

SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2025-01-31zacks.com

Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up

2025-01-30zacks.com

Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics

2025-01-30zacks.com

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

2025-01-23zacks.com

Here's Why You Should Add Surmodics Stock to Your Portfolio Now

2025-01-14zacks.com

After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)

2025-01-03zacks.com

SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717
fillingDate 2024-11-20 2024-07-31 2024-05-01 2024-02-01 2023-11-22 2023-08-02 2023-04-26 2023-02-06 2022-11-23
acceptedDate 2024-11-20 08:47:29 2024-07-31 08:00:27 2024-05-01 08:15:30 2024-02-01 08:15:27 2023-11-22 10:22:11 2023-08-02 08:16:08 2023-04-26 08:16:12 2023-02-06 17:21:13 2022-11-23 08:55:51
calendarYear 2024 2024 2024 2024 2023 2023 2023 2023 2022
period Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4
revenue 33M 30M 32M 31M 28M 52M 27M 25M 26M
costOfRevenue 9M 9M 8M 17M 17M 18M 19M 18M 18M
grossProfit 25M 21M 24M 13M 11M 34M 9M 7M 8M
grossProfitRatio 0.739 0.693 0.75 0.428 0.402 0.654 0.314 0.278 0.313
researchAndDevelopmentExpenses 3M 10M 10M 3M 3M 3M 2M 2M 2M
generalAndAdministrativeExpenses 0 17M 13M 0 26M 13M 13M 0 0
sellingAndMarketingExpenses 0 -1 0 0 -3000 0 3000 0 0
sellingGeneralAndAdministrativeExpenses 15M 17M 13M 13M 13M 13M 13M 13M 14M
otherExpenses 8M 8M 9M 7M -339 000 835 000 -2M -1M -1M
operatingExpenses 25M 26M 23M 13M 14M 14M 14M 14M 15M
costAndExpenses 34M 36M 31M 31M 30M 32M 32M 32M 33M
interestIncome 0 0 0 539 000 546 000 0 0 0 0
interestExpense 884 000 879 000 881 000 896 000 895 000 884 000 884 000 826 000 188 000
depreciationAndAmortization 2M 2M 2M 43 276 2M 2M 3M 2M 2M
ebitda 1M -3M 3M 2M -293 000 24M -2M -5M -4M
ebitdaratio 0.03 -0.107 0.086 0.066 -0.01 0.449 -0.071 -0.205 -0.168
operatingIncome -613 000 -5M 659 000 -322 000 -2M 21M -5M -7M -7M
operatingIncomeRatio -0.018 -0.177 0.021 -0.011 -0.088 0.408 -0.195 -0.29 -0.254
totalOtherIncomeExpensesNet -524 000 -442 000 -493 000 494 000 -339 000 956 000 -2M -779 000 -179 000
incomeBeforeTax -1M -6M 166 000 -724 000 -3M 21M -7M -8M -7M
incomeBeforeTaxRatio -0.034 -0.192 0.005 -0.024 -0.1 0.393 -0.271 -0.321 -0.261
incomeTaxExpense 2M 2M -81 000 62 000 -9M 13M 368 000 -165 000 8M
netIncome -3M -8M 247 000 -786 000 7M 7M -8M -8M -15M
netIncomeRatio -0.104 -0.249 0.008 -0.026 0.239 0.14 -0.284 -0.315 -0.567
eps -0.24 -0.53 0.017 -0.056 0.48 0.52 -0.55 -0.56 -1.06
epsdiluted -0.24 -0.53 0.017 -0.056 0.47 0.52 -0.55 -0.56 -1.06
weightedAverageShsOut 14M 14M 14M 14M 14M 14M 14M 14M 14M
weightedAverageShsOutDil 14M 14M 14M 14M 14M 14M 14M 14M 14M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717
fillingDate 2024-11-20 2024-07-31 2024-05-01 2024-02-01 2023-11-22 2023-08-02 2023-04-26 2023-02-06 2022-11-23
acceptedDate 2024-11-20 08:47:29 2024-07-31 08:00:27 2024-05-01 08:15:30 2024-02-01 08:15:27 2023-11-22 10:22:11 2023-08-02 08:16:08 2023-04-26 08:16:12 2023-02-06 17:21:13 2022-11-23 08:55:51
calendarYear 2024 2024 2024 2024 2023 2023 2023 2023 2022
period Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4
cashAndCashEquivalents 36M 24M 33M 23M 41M 45M 19M 26M 19M
shortTermInvestments 4M 14M 8M 12M 4M 0 0 0 0
cashAndShortTermInvestments 40M 38M 41M 35M 45M 45M 19M 26M 19M
netReceivables 23M 24M 24M 27M 19M 24M 20M 17M 24M
inventory 15M 15M 15M 14M 15M 15M 14M 13M 12M
otherCurrentAssets 3M 3M 4M 17M 8M 15M 8M 8M 3M
totalCurrentAssets 81M 80M 84M 80M 87M 86M 61M 64M 58M
propertyPlantEquipmentNet 25M 29M 29M 29M 26M 30M 28M 28M 31M
goodwill 45M 43M 44M 44M 43M 44M 44M 43M 41M
intangibleAssets 24M 24M 25M 26M 26M 28M 29M 29M 28M
goodwillAndIntangibleAssets 68M 67M 68M 70M 69M 72M 73M 73M 69M
longTermInvestments 0 -2M -2M -2M 0 -2M 0 0 0
taxAssets 0 2M 2M 2M 0 2M 2M 2M 0
otherNonCurrentAssets 4M 1M 1M 724 000 4M 2M 3M 3M 1M
totalNonCurrentAssets 97M 97M 99M 100M 99M 103M 105M 105M 101M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 179M 177M 183M 180M 186M 189M 166M 170M 158M
accountPayables 0 3M 3M 3M 3M 2M 4M 2M 3M
shortTermDebt 0 1M 1M 997 000 872 000 1M 1M 1M 11M
taxPayables 1M 43 000 0 0 0 12M 36 000 0 0
deferredRevenue 2M 4M 5M 4M 4M 4M 3M 4M 4M
otherCurrentLiabilities 18M 12M 10M 9M 16M 24M 11M 10M 14M
totalCurrentLiabilities 21M 20M 19M 16M 24M 32M 19M 17M 32M
longTermDebt 30M 32M 29M 33M 29M 32M 29M 29M 4M
deferredRevenueNonCurrent 0 3M 3M 2M 2M 3M 3M 4M 5M
deferredTaxLiabilitiesNonCurrent 0 5M 5M 2M 2M 2M 2M 2M 2M
otherNonCurrentLiabilities 10M 7M 2M 5M 8M 6M 10M 10M -371 000
totalNonCurrentLiabilities 39M 39M 40M 42M 42M 44M 44M 45M 18M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 0 4M 3M 4M 4M 4M 4M 5M 5M
totalLiabilities 60M 59M 59M 58M 66M 76M 64M 62M 50M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 0 713 000 713 000 712 000 708 000 707 000 707 000 706 000 701 000
retainedEarnings 0 79M 87M 86M 87M 81M 73M 81M 89M
accumulatedOtherComprehensiveIncomeLoss -2M -4M -4M -3M -5M -3M -4M -5M -10M
othertotalStockholdersEquity 121M 42M 40M 38M 37M 34M 32M 30M 29M
totalStockholdersEquity 119M 118M 124M 122M 120M 112M 103M 107M 108M
totalEquity 119M 118M 124M 122M 120M 112M 103M 107M 108M
totalLiabilitiesAndStockholdersEquity 179M 177M 183M 180M 186M 189M 166M 170M 158M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 179M 177M 183M 180M 186M 189M 166M 170M 158M
totalInvestments 4M 14M 8M 12M 4M -2M 0 0 0
totalDebt 30M 33M 34M 34M 29M 33M 29M 31M 15M
netDebt -7M 9M 631 000 11M -12M -11M 10M 4M -4M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX SRDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717 924 717
fillingDate 2024-11-20 2024-07-31 2024-05-01 2024-02-01 2023-11-22 2023-08-02 2023-04-26 2023-02-06 2022-11-23
acceptedDate 2024-11-20 08:47:29 2024-07-31 08:00:27 2024-05-01 08:15:30 2024-02-01 08:15:27 2023-11-22 10:22:11 2023-08-02 08:16:08 2023-04-26 08:16:12 2023-02-06 17:21:13 2022-11-23 08:55:51
calendarYear 2024 2024 2024 2024 2023 2023 2023 2023 2022
period Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4
netIncome -3M -8M 247 000 -786 000 7M 7M -8M -8M -15M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M 2M 2M 2M
deferredIncomeTax -58 000 -73 000 -92 000 -97 000 6000 30 000 -110 000 -107 000 8M
stockBasedCompensation 0 2M 2M 2M 2M 2M 2M 2M 2M
changeInWorkingCapital 3M 1M 3M -12M -10M 15M -2M -7M -359 000
accountsReceivables 297 000 -1M -907 000 -3M 3M 3M 0 546 000 0
inventory 238 000 -1000 -966 000 401 000 -230 000 -842 000 -1M -905 000 -893 000
accountsPayables -417 000 181 000 432 000 -428 000 486 000 -948 000 2M -1M 1M
otherWorkingCapital 3M 2M 4M -9M -13M 14M -3M -6M -725 000
otherNonCashItems 2M 7M 8M 142 000 123 000 -513 000 356 000 374 000 224 000
netCashProvidedByOperatingActivities 4M -2M 7M -9M 1M 26M -6M -11M -3M
investmentsInPropertyPlantAndEquipment -542 000 -959 000 -1M -720 000 -748 000 -470 000 -723 000 -977 000 -572 000
acquisitionsNet 0 0 0 8M 0 0 0 0 0
purchasesOfInvestments 0 -12M -4M -10M -4M 0 0 0 0
salesMaturitiesOfInvestments 10M 6M 8M 2M 0 0 0 0 2M
otherInvestingActivites 0 -6M 4M -8M -4M 0 0 0 0
netCashUsedForInvestingActivites 9M -7M 3M -8M -5M -470 000 -723 000 -977 000 1M
debtRepayment 0 0 0 0 -10M 0 0 -10M 0
commonStockIssued 553 000 93 000 531 000 39 000 449 000 0 456 000 347 000 483 000
commonStockRepurchased 0 0 -5000 -1M -30 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -2M -27 000 -936 000 -1M 10M -19 000 -1M 28M -185 000
netCashUsedProvidedByFinancingActivities -2M 66 000 -405 000 -1M 419 000 -19 000 -794 000 19M 298 000
effectOfForexChangesOnCash 260 000 -40 000 -132 000 247 000 -177 000 -3000 92 000 411 000 -302 000
netChangeInCash 12M -9M 10M -18M -3M 25M -7M 7M -1M
cashAtEndOfPeriod 36M 24M 33M 23M 41M 45M 19M 26M 19M
cashAtBeginningOfPeriod 24M 33M 23M 41M 45M 19M 26M 19M 20M
operatingCashFlow 4M -2M 7M -9M 1M 26M -6M -11M -3M
capitalExpenditure -542 000 -959 000 -1M -720 000 -748 000 -470 000 -723 000 -977 000 -572 000
freeCashFlow 3M -3M 6M -10M 502 000 25M -7M -12M -3M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-01 ET (fiscal 2024 q2)
2023 q4
2024-02-01 ET (fiscal 2024 q1)
2023 q3
2023-11-10 ET (fiscal 2023 q4)
2023 q2
2023-08-06 ET (fiscal 2023 q3)
2023 q1
2023-04-26 ET (fiscal 2023 q2)
2022 q4
2023-02-06 ET (fiscal 2023 q1)
2022 q3
2022-11-12 ET (fiscal 2022 q4)
2022 q2
2022-07-27 ET (fiscal 2022 q3)
2022 q1
2022-04-27 ET (fiscal 2022 q2)
2021 q4
2022-02-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-06 12:00 ET
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
2024-10-30 18:30 ET
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
2024-10-01 11:00 ET
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
2024-07-31 11:00 ET
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
2024-06-10 11:00 ET
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
2024-05-29 14:23 ET
SRDX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Surmodics to GTCR
2024-05-29 11:00 ET
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
2024-05-01 11:00 ET
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
2024-04-19 11:00 ET
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
2024-02-27 13:00 ET
Surmodics to Participate in Upcoming Investor Conferences in March and April
2024-02-01 12:00 ET
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
2024-01-22 12:30 ET
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
2024-01-16 12:30 ET
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
2024-01-16 12:30 ET
Surmodics to Host Virtual Annual Meeting of Shareholders
2023-11-16 12:30 ET
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
2023-11-16 12:30 ET
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
2023-11-14 21:05 ET
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
2023-11-08 12:30 ET
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
2023-11-07 12:30 ET
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
2023-11-07 12:30 ET
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
2023-10-31 11:30 ET
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
2023-10-10 11:30 ET
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
2023-08-09 21:05 ET
Surmodics to Participate in Upcoming Investor Conferences in August
2023-08-02 11:31 ET
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
2023-07-12 11:30 ET
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
2023-06-20 10:30 ET
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
2023-06-14 11:30 ET
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
2023-05-25 20:05 ET
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
2023-04-26 11:00 ET
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
2023-04-20 11:05 ET
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
2023-04-19 11:30 ET
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26
2023-04-19 11:00 ET
Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery
2023-04-11 12:30 ET
Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20
2023-03-28 13:25 ET
Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
2023-03-08 13:30 ET
Surmodics to Participate in Upcoming Investor Conferences in March
2023-02-06 21:05 ET
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
2023-01-31 13:30 ET
Surmodics to Host Virtual Annual Meeting of Shareholders
2023-01-26 13:30 ET
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
2023-01-19 13:30 ET
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
2023-01-19 12:00 ET
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
2023-01-16 13:30 ET
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
2022-11-17 13:30 ET
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
2022-11-11 13:30 ET
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
2022-11-09 12:00 ET
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
2022-11-02 12:30 ET
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
2022-10-28 11:30 ET
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
2022-10-26 12:30 ET
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
2022-10-17 12:30 ET
Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing
2022-10-11 12:30 ET
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
2022-10-07 12:30 ET
6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe
2022-08-23 12:30 ET
Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
2022-07-27 11:30 ET
Surmodics Reports Third Quarter Fiscal 2022 Results
2022-07-19 12:30 ET
Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27
2022-06-01 12:30 ET
Surmodics to Present at Jefferies Healthcare Conference
2022-04-27 11:30 ET
Surmodics Reports Second Quarter Fiscal 2022 Results
2022-04-27 11:15 ET
Pounce™ Thrombectomy System First-in-Human Data Show 100 Percent Technical Success in Early Cases
2022-04-25 12:25 ET
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
2022-04-19 12:30 ET
Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27
2022-02-04 13:30 ET
Surmodics to Host Virtual Annual Meeting of Shareholders
2022-02-03 12:30 ET
Surmodics Reports First Quarter Fiscal 2022 Results
2022-01-26 13:30 ET
Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3
2022-01-11 13:35 ET
Surmodics to Present at Sidoti & Company Virtual Investor Conference
2021-11-10 12:30 ET
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
2021-11-02 12:30 ET
Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10
2021-09-29 12:15 ET
Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter
2021-08-04 11:30 ET
Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance
2021-07-29 12:30 ET
Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System
2021-07-27 12:30 ET
Surmodics to Webcast Third Quarter Fiscal 2021 Earnings Conference Call on August 4

SEC forms

Show financial reports only

SEC form 8
2025-04-30 00:00 ET
Surmodics published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Surmodics published news for 2025 q1
SEC form 10
2025-04-30 00:00 ET
Surmodics reported for 2025 q1
SEC form 10
2025-01-30 07:55 ET
Surmodics reported for 2024 q4
SEC form 8
2025-01-30 07:00 ET
Surmodics reported for 2024 q4
SEC form 8
2025-01-30 07:00 ET
Surmodics published news for 2024 q4
SEC form 10
2025-01-30 00:00 ET
Surmodics reported for 2024 q4
SEC form 10
2024-11-20 08:47 ET
Surmodics reported for 2024 q3
SEC form 10
2024-11-20 00:00 ET
Surmodics published news for 2024 q3
SEC form 8
2024-11-06 07:00 ET
Surmodics published news for 2024 q3
SEC form 8
2024-11-06 07:00 ET
Surmodics published news for 2024 q3
SEC form 10
2024-07-31 08:00 ET
Surmodics reported for 2024 q2
SEC form 8
2024-07-31 07:00 ET
Surmodics published news for 2024 q2
SEC form 8
2024-07-31 07:00 ET
Surmodics published news for 2024 q2
SEC form 10
2024-07-31 00:00 ET
Surmodics published news for 2024 q2
SEC form 10
2024-05-01 08:15 ET
Surmodics published news for 2024 q1
SEC form 8
2024-05-01 07:00 ET
Surmodics published news for 2024 q1
SEC form 8
2024-05-01 07:00 ET
Surmodics reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
Surmodics published news for 2024 q1
SEC form 8
2024-02-01 00:00 ET
Surmodics published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Surmodics reported for 2023 q4
SEC form 10
2024-02-01 00:00 ET
Surmodics reported for 2023 q4
SEC form 10
2023-11-22 00:00 ET
Surmodics published news for 2023 q3
SEC form 8
2023-11-08 07:00 ET
Surmodics reported for 2023 q3
SEC form 10
2023-08-02 08:16 ET
Surmodics reported for 2023 q2
SEC form 6
2023-08-02 07:01 ET
Surmodics published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Surmodics published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Surmodics published news for 2023 q2
SEC form 6
2023-07-26 08:00 ET
Surmodics published news for 2023 q2
SEC form 6
2023-06-20 06:31 ET
Surmodics published news for 2023 q1
SEC form 6
2023-06-08 08:01 ET
Surmodics published news for 2023 q1
SEC form 10
2023-04-26 00:00 ET
Surmodics published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
Surmodics published news for 2023 q1
SEC form 6
2023-03-28 10:40 ET
Surmodics published news for 2022 q4
SEC form 6
2023-03-15 08:31 ET
Surmodics published news for 2022 q4
SEC form 6
2023-02-13 16:05 ET
Surmodics published news for 2022 q4
SEC form 10
2023-02-06 17:21 ET
Surmodics reported for 2022 q4
SEC form 6
2023-02-06 16:01 ET
Surmodics published news for 2022 q4
SEC form 10
2023-02-06 00:00 ET
Surmodics reported for 2022 q4
SEC form 8
2023-02-06 00:00 ET
Surmodics reported for 2022 q4
SEC form 6
2023-02-03 16:10 ET
Surmodics published news for 2022 q4
SEC form 6
2023-01-19 07:10 ET
Surmodics published news for 2022 q4
SEC form 6
2022-12-19 16:25 ET
Surmodics published news for 2022 q3
SEC form 10
2022-11-23 08:55 ET
Surmodics reported for 2022 q3
SEC form 10
2022-11-23 00:00 ET
Surmodics reported for 2022 q3
SEC form 6
2022-11-09 07:01 ET
Surmodics published news for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Surmodics reported for 2022 q3
SEC form 6
2022-10-17 08:01 ET
Surmodics published news for 2022 q3
SEC form 6
2022-08-31 08:30 ET
Surmodics published news for 2022 q2
SEC form 10
2022-07-27 14:09 ET
Surmodics reported for 2022 q2
SEC form 6
2022-07-27 07:35 ET
Surmodics published news for 2022 q2
SEC form 10
2022-07-27 00:00 ET
Surmodics reported for 2022 q2
SEC form 8
2022-07-27 00:00 ET
Surmodics reported for 2022 q2
SEC form 10
2022-04-27 14:35 ET
Surmodics reported for 2022 q1
SEC form 6
2022-04-27 07:35 ET
Surmodics published news for 2022 q1
SEC form 10
2022-04-27 00:00 ET
Surmodics reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
Surmodics reported for 2022 q1
SEC form 6
2022-03-07 16:47 ET
Surmodics published news for 2021 q4
SEC form 6
2022-02-14 16:27 ET
Surmodics published news for 2021 q4
SEC form 10
2022-02-04 00:00 ET
Surmodics published news for 2021 q4
SEC form 10
2022-02-03 21:17 ET
Surmodics published news for 2021 q4
SEC form 6
2022-02-03 07:35 ET
Surmodics published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Surmodics published news for 2021 q4
SEC form 6
2022-01-11 08:30 ET
Surmodics published news for 2021 q4
SEC form 6
2021-12-20 16:05 ET
Surmodics published news for 2021 q3
SEC form 10
2021-11-24 11:36 ET
Surmodics published news for 2021 q3
SEC form 10
2021-11-24 00:00 ET
Surmodics published news for 2021 q3
SEC form 6
2021-11-10 07:35 ET
Surmodics published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Surmodics published news for 2021 q3
SEC form 10
2021-08-04 08:44 ET
Surmodics published news for 2021 q2
SEC form 6
2021-08-04 07:35 ET
Surmodics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Surmodics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Surmodics published news for 2021 q2
SEC form 6
2021-07-06 08:10 ET
Surmodics published news for 2021 q2
SEC form 10
2021-04-28 15:47 ET
Surmodics published news for 2021 q1
SEC form 6
2021-04-28 07:35 ET
Surmodics published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
Surmodics published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
Surmodics published news for 2021 q1
SEC form 6
2021-02-16 16:30 ET
Surmodics published news for 2020 q4
SEC form 10
2021-02-09 08:50 ET
Surmodics published news for 2020 q4
SEC form 6
2021-02-09 07:35 ET
Surmodics published news for 2020 q4
SEC form 6
2021-01-28 16:35 ET
Surmodics published news for 2020 q4
SEC form 6
2020-12-22 16:31 ET
Surmodics published news for 2020 q3
SEC form 10
2020-12-02 13:10 ET
Surmodics published news for 2020 q3
SEC form 6
2020-11-18 16:05 ET
Surmodics published news for 2020 q3
SEC form 6
2020-11-04 16:15 ET
Surmodics published news for 2020 q3